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e.2012.02Abstract Aim: The aim of the current study is to detect CTCs in the blood of breast cancer
females by the expression of Mammoglobin and Mucin-1 to evaluate their potential as diagnostic
and prognostic markers of breast cancer and predictors of metastasis.
Subjects and methods: The study involved 50 patients and thirty controls. Fifty patients recently
diagnosed with breast cancer were proved by ﬁne needle aspiration cytology or core biopsy, all
the patients were operated upon by modiﬁed radical mastectomy under general anesthesia after
complete preoperative evaluation. From each subject a blood sample was drawn before surgery,
2 weeks after surgery and after 6 cycles of chemotherapy. Mononuclear cells were separated from
7.5 ml blood using a phicoll gradient. From these cells mRNA was extracted, and RT-PCR was car-
ried out to detect Mammoglobin and Mucin-1 gene expression from CTCs. Also CA 15.3 was mea-
sured in all the samples.
Results: CTCs were detected in more than 80% of primary breast cancer patients at presentation,
that percent decreased after surgery and after adjuvant chemotherapy. CTCs detection after surgery
and after chemotherapy was signiﬁcantly correlated with tumor size, grad, vascular invasion and
metastasis. CTCs posed an almost two-fold risk of metastasis and signiﬁcantly lower DFS time
in positive than in negative patients. Detection of CTCs in peripheral blood after chemotherapy
successfully predicted subsequent metastasis.
Conclusion: The hematogenous spread of tumor cells in patients with breast cancer may be an early
phenomenon occurring before/apart from regional lymph nodes involvement. CTCs detection by
RT-PCR could add to the initial evaluation of primary breast cancer patients. Also, adjuvantri.edu.eg (E.RE. Zaher).
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198 S.A. Ebeed et al.chemotherapy might eliminate or decrease occult tumor cells. But CTCs evaluation after adjuvant
chemotherapy could predict metastasis and the presence of CTCs after chemotherapy reﬂect a
higher potential for subsequent metastasis.
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reserved.1. Introduction
Breast cancer is a major public health problem for women
throughout the world. It is the most frequent cancer in women
and the second leading cause of death.1 In Alexandria, Egypt,
breast cancer incidence was estimated to be 41.2% of all malig-
nancies in females in 2007.2
Some of the key decisions in the current management of
primary breast cancer involve the need for prognostication;
which is especially important in identifying patients whose
prognosis is so favorable or patients whose prognosis is so
poor with conventional treatment as to warrant consideration
of more aggressive investigational therapies. The most useful
and consistent of these prognostic factors are the number of
positive axillary nodes, tumor size, poor differentiation, vascu-
lar invasion and estrogen and progesterone receptors.3 In addi-
tion, breast cancer is a leading cause of mortality; primarily
due to the failure of effective clinical detection and the treat-
ment of metastatic diseases. Up to 30% of patients still suc-
cumb to the disease within the ten-year period following
diagnosis.4,5 It remains difﬁcult to accurately predict which pa-
tients will develop metastatic disease and over what time scale.
The metastatic process is comprised of a series of sequential
steps, including dissemination of cancer cells from the primary
tumor into the blood stream (intravasation), survival in circu-
lation, arrest and extravasation in a secondary site and initia-
tion and maintenance of growth to form clinically detectable
masses. Cancer cells must successfully complete all steps to
form a metastatic tumor.6–8
Given the multistep nature of metastatic cascade, there
should be several opportunities for early identiﬁcation and
therapeutic targeting of metastatic cells before they become a
clinical problem. In fact, there is growing evidence that the
presence of circulating tumor cells (CTCs) in the blood may
be an important indicator of the potential for metastatic dis-
ease and poor prognosis.9,10
The ability to consistently detect, track and characterize rare
CTCs in cancer patients holds tremendous promise in terms of
identifying the potential for metastatic disease at very early
stages, managing risk stratiﬁcation in the adjuvant setting,
monitoring response to treatment and monitoring disease
recurrence. Identiﬁcation of CTCs in blood depends on exploit-
ing phenotypic differences between epithelial tumor cells and
cells of hematopoietic origin using either tumor-type-speciﬁc
markers or epithelial-speciﬁc markers.10
The aim of the current study is to detect CTCs in the blood
of breast cancer females by the expression of Mammoglobin
and Mucin-1 to evaluate their potential as diagnostic and
prognostic markers of breast cancer, and predictors of metas-
tasis. In a preliminary study on 30 breast cancer patients that
was carried out in our lab, the results were inclusive, so, thisstudy was carried out with a larger cohort hoping to reach
more conclusive results.
2. Subjects and methods
2.1. Subjects
The study was approved by the Ethics Committee and by the
Institutional Review Board of the Medical Research Institute,
Alexandria University, Egypt. All samples were collected with
the patients’ informed written consent, and conﬁdentiality of
data was insured at all stages of the study.
For this prospective cohort study, ﬁfty females recently
diagnosed with breast cancer were randomly recruited from
the Experimental and Clinical Surgery Department and Can-
cer Management and Research Department, Medical Research
Institute, Alexandria University, during the period from Sep-
tember 2007 till October 2008. All patients were premenopau-
sal females, diagnosed with primary breast cancer, as indicated
by ﬁne-needle biopsy or core biopsy. Eligibility criteria in-
cluded conﬁrmed diagnosis of breast cancer, no metastasis at
the time of recruitment, no previous treatment, no previous
malignancies and good cardiac, liver and kidney function.
All patients were subjected to complete physical examination
and a complete diagnostic evaluation to exclude the presence
of distant metastases, consisting of chest X-rays, ultrasound
of the liver, and a whole-body bone scan. Computed tomogra-
phy scans and/or magnetic resonance imaging studies were
performed if clinically indicated.
An informed written consent was taken from each patient.
All patients were treated primarily with Modiﬁed Radical
Mastectomy,11 followed adjuvant FAC-based combination
chemotherapy (6 cycles each one consisted of 5-ﬂourouracil
500 mg/m2, adriamycin 50 mg/m2 and cyclophosphamide
500 mg/m2, given every 21 days). Patients who were positive
for estrogen and progesterone receptors received hormonal
therapy (Nolvadex tablets 10 mg, 2 tablets/day for 5 years)
after chemotherapy.12 Patients were clinically followed up for
48 months after completing chemotherapy.
In addition, thirty normal, healthy volunteer females of
matched age as the patients group, were included as a control
group.
2.2. Sampling
From each subject 10-ml venous blood samples were collected,
once from control subjects and 3 times from group 1 patients
(before surgery, 2 weeks after surgery and after 6 cycles of che-
motherapy). 7.5 ml was processed using gradient centrifuga-
tion by Ficol-Paque Plus (Biochrom AG, Berlin, Germany)
to obtain the buffy layer that would contain CTCs, if present,
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and then pelleted and stored. The remaining 2.5 ml of blood
was left to clot then centrifuged to obtain serum. All cells
and serum samples were stored at 80 C until they were used.
2.3. RNA extraction
Total RNA was extracted from all cell samples using the SV
Total RNA Isolation System (Promega Corporation, Madi-
son, USA), the procedure was carried according to the manu-
facturer’s instructions. Cells were thawed in lysis buffer, then
diluted and centrifuged at 12,000–14,000·g for 10 min to re-
move the cell debris. RNA was precipitated from the cleared
lysate using 95% ethanol and separated through spin columns,
where RNA is washed and treated by DNase and washed
again before it was eluted by 100 ll of nuclease-free water.
The amount of total RNA extracted was assessed spectro-
photometrically using NanoDrop ND-1000 UV–Vis Spectro-
photometer to measure the optical density at 230, 260 and
280 nm. All samples included in the study had A260/A280 ratio
ranging from 1.7 to 2.1.
2.4. RT-PCR for Mammoglobin and Mucin-1
Reverse transcription was carried out using Reverse Transcrip-
tion System (Promega, Madison, USA) that used AMV Re-
verse Transcriptase and oligo (dT)15 primer to synthesize
single-stranded cDNA from total RNA according to the man-
ufacturer’s instructions.
PCR was carried out using Go TaqGreen Master Mix
(Promega Corporation, Madison, USA). Each PCR reaction
mixture consisted of 12.5 ll PCR master mix; 1 ll of each
ampliﬁcation primer (400 pmol/ll) and 1 lg cDNA and the
volume was brought to 25 ll by adding deionized water. The
primers used for the ampliﬁcations were as follows; Mammo-
globin F-50-CGGATGAAACTCTGAGCAATGT and R-50-
CTGCAGTTCTGTGAGCCAAAG to produce a 108 bp frag-
ment, Mucin-1 F-50-ACTACTACCAAGAGCTG and R-50-
CTCATAGGATGGTAGGT to produce a 238 bp fragment,
and b-actin as a house-keeping gene F-50-ATGCCATCCTGC
GTCTGGACCTGGC and R-50-AGCATTTGCGGTGCGA-
CATGGAGGG to produce a 607 bp fragment. Thermal cy-
cling started by a ﬁrst denaturation step of 4 min at 95 C,
followed by 40 cycles of 94 C for 30 s, 64 C for 30 s and
72 C for 60 s and a ﬁnal extention at 72 C for 10 min.
PCR products were then separated by gel electrophoresis,
stained by ethedium bromide, visualized by UV and
photographed.
2.5. Measurement of CA 15.3 by IRMA
CA 15.3 was measured in all serum samples collected by
Immunoradiometric Assay (IRMA) using a commercially
available kit (DIAsource ImmunoAssays S.A., Nivelles, Bel-
gium). According to maneufacturer’s instructions, 20 ll of
each sample was diluted with 500 ll diluent and 50 ll of di-
luted sample or calibrator was dispensed into antibody-coated
tubes. The tubes were aspirated and washed twice, then 50 ll
of 125I-labeled anti-CA 15.3 was added to each tube, after incu-
bated for 90 min/RT on shaker, tubes were aspirated and
washed twice, and counted on a Gamma Counter. Sample con-centrations were determined by interpolation from the stan-
dard curve.
2.6. Statistical analysis
Statistical analysis was performed using the SPSS (Statistical
Package for the Social Sciences) software version 18.0 (SPSS
Inc., Chicago, IL, USA).
2.6.1. Variables manipulation
The CA 15.3 was converted from a quantitative variable to a
dichotomous variable using its median value among the con-
trols as the cut off level criterion. Estrogen receptor (ER), pro-
gesterone receptor (PR), Mammoglobin, and Mucin-1 were
also converted to dichotomous variables either negative or po-
sitive by combining several grades of positivity into positive.
2.6.2. Data analysis
For variables’ description, the percent was used for qualitative
variables and the mean with the standard deviation for quan-
titative normally distributed variables, while the not normally
distributed variables were described by the median and range.
Testing the changes in percentage positives for the biochemical
parameters at different times; before surgery, after 2 weeks of
surgery and after 6 cycles of treatment was done using the
Cochran’s Q test. The relative risk with its 95% conﬁdence
interval was used to assess the risk of metastasis among those
whose biochemical parameters were positive relative to those
whose biochemical parameters were negative. Relative risk of
value 1 indicates no risk and relative risk more than 1 indicates
an increased risk. To be signiﬁcant, the 95% conﬁdence inter-
val should not include 1.0. The cumulative proportion metas-
tasis free surviving through the follow up duration was
illustrated via the Kaplan–Meier survival curve, using the
mean survival time and its 95% conﬁdence interval as descrip-
tive for the different survival times. Comparisons between the
different survival distributions were done using the logrank
test. The prognostic accuracy for the biochemical parameters
before surgery, 2 weeks after surgery and 6 cycles after treat-
ment was demonstrated by the different Receiver Operating
Characteristic (ROC) Curves, the areas under the curves
(AUCs) were indicators for the accuracy of the biochemical
parameter. For the AUC to be signiﬁcant its 95% lower con-
ﬁdence interval should be above .50. All tests were 2 sided
and alpha was set at 0.05.3. Results
3.1. Description of the study sample
A cohort of ﬁfty breast cancer females with a mean age and
standard deviation of 45 ± 4.6 years, the mean tumor size
was 3.2 ± 1.7 cm. Half the cohort (50%) had moderately dif-
ferentiated tumor while 48% had poorly differentiated tumor.
The median number of lymph nodes metastasis was 2 ranging
from 0 to 15. More than half the sample (58.0%) had vascu-
lar invasion and the majority were either stage 2 (56%) or
stage 3 (40%). Positive estrogen receptor and positive proges-
terone receptor were each present in 84% of the cohort;
(Table 1).
Table 1 Description of the females cancer breast patients by clinic pathological parameters (n= 50).
Clinico-pathological parameter N %
Age in years (X S) 45 ± 4.6
Tumor size in cms (X S) 3.2 ± 1.7
Grade of diﬀerentiation 1 1 2.0
2 25 50.0
3 24 48.0
Lymph node metastasis (Mdn, range) 2 (0–15)
+ve Vascular invasion 29 58.0
Stage 1 1 2.0
2 28 56.0
3 21 42.0
Estrogen receptor+ve 42 84.0
Progesterone receptor+ve 42 84.0
Figure 1 Gel electrophoresis of RT-PCR products of Mammo-
globin (108 bp), Mucin-1 (238 bp) and b-actin (607 bp).
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15.3 levels at different study points
Fig. 1 represents the gel electrophoresis of the RT-PCR
products showing the 108 bp band of Mammoglobin,
238 bp band of Mucin-1 and the 607 bp band of the house
keeping gene b-actin. For Mammoglobin, 80% showed posi-
tive expression before surgery, 60% after surgery while 54%
after treatment. These differences were statistically signiﬁcant
(Cochran’s Q= 14.70, p= 0.001). Similarly, Mucin-1
expression was positive in 86% before surgery, in 84% after
surgery, while in 54% after treatment. These differences were
also statistically signiﬁcant (Cochran’s Q= 22.21,
p< 0.001). Regarding CA 15.3, a reversed pattern was ob-
served, where the positive percent was 20% before surgery,
24% after surgery, while 44% after treatment. These differ-
ences were also statistically signiﬁcant (Cochran’s
Q= 13.78, p= 0.001); (Table 2).
3.3. Diagnostic potential of Mammoglobin, Mucin-1 and CA
15.3 for breast cancer
Expression of Mammoglobin and Mucin-1 before surgery
proved a statistically signiﬁcant diagnostic accuracy for breast
cancer (p= 0.000 and 0.000, respectively) (Fig. 2). Mammo-
globin had an AUC= 0.90, 95% at CI: 0.829, 0.971, with a
corresponding sensitivity of 80% and speciﬁcity of 100%.
While Mucin-1 had an AUC= 0.93, 95% at CI: 0.870,
0.990, with a corresponding sensitivity of 86% and speciﬁcity
of 100%. While CA 15.3 was not of any diagnostic signiﬁcance
with an AUC= 0.263, 95% CI: 0.142, 0.384, the best cut off
point was 12.5 ng/ml with a sensitivity of 42% and a speciﬁcity
of 22%.Table 2 Changes in the percentage expression of all parameters; be
Biochemical parameter Before Surgery After surgery
n (%) n (%)
Mammoglobin+ve 40 (80) 30 (60)
Mucin-1+ve 43 (86) 42 (84)
CA 15.3+ve 10 (20) 12 (24)
** Cochran’s Q test.
* Highly signiﬁcant.Before surgery, neither Mammoglobin nor Mucin-1 expres-
sion showed a signiﬁcant correlation with any of the clinical
parameters involved in breast cancer. While after surgery
and after chemotherapy, Mammoglobin and Mucin-1 were sig-fore surgery, 2 weeks after surgery, & after 6 cycles of treatment.
After treatment Test of signiﬁcance** P value
n (%)
27 (54) 14.70 0.001*
28 (54) 22.21 0.001*
22 (44) 13.78 0.001*
Figure 2 ROC curve of Mammoglobin, Mucin 1 and CA 15.3 as
diagnostic markers for breast cancer before surgery.
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sis. Only Mucin-1 correlated with tumor size and only Mam-
moglobin correlated with lymph node metastasis (Table 3).
Other parameters including age, ER, PR and grade were not
correlated with either Mammoglobin or Mucin-1 at any time.
Mammoglobin and Mucin-1 were correlated with each other atTable 3 Correlations between Mammoglobin and Mucin-1, 2 week
clinical parameters.
Parameter Mammoglobin (r,p)*
After surgery After treatment
Tumor size
Stage 0.320
Vascular invasion 0.296 0.037 0.353
Lymph node metastasis 0.320
Metastasis 0.320 0.023 0.333
Mucin-1 0.625 0.000 0.491
* r is Spearman’s two-tailed correlation coefﬁcient and p is the signiﬁcan
Table 4 The relative risk for breast cancer metastasis according to
Biochemical parameter No Metastasis (28)
n (%)
Mammoglobin
ve** 14 (66.6)
+ve 14 (48.3)
Mucin-1
ve** 8 (100.0)
+ve 20 (47.6)
CA 15.3
ve** 23 (60.5)
+ve 5 (41.7)
* Signiﬁcant.
** Reference category.all times. CA 15.3 did not show any correlation with any of the
clinical parameters evaluated at any time.
3.4. The relative risks for metastasis estimated at different study
points
Before surgery, the relative risk of metastasis was not signiﬁ-
cantly higher in Mammoglobin positive (RR = 1.6, 95% CI:
1.03, 2.48), Mucin-1 positive (RR = 1.3, 95% CI: .77, 2.30)
and CA 15.3 positive (RR = 1.1, 95% CI: 0.59, 2.26). After
2 weeks of surgery, the relative risk of metastasis was signiﬁ-
cantly higher only in Mucin-1 positive (RR = 2.1, 95% CI:
1.52, 2.88) but no signiﬁcant risk was detected either in Mam-
moglobin positive or in CA 15.3 positive (Table 4). After 6 cy-
cles of treatment, the relative risk of metastasis was
signiﬁcantly higher both in Mammoglobin positive relative
to Mammoglobin negative (RR = 1.8, 95% CI: 1.10, 3.04),
and in Mucin-1 positive relative to Mucin-1 negative
(RR = 1.8, 95% CI: 1.03, 2.79) meanwhile no signiﬁcant risk
was observed in CA 15.3 positive (RR = 1.7, 95% CI: 0.94,
2.91) (Table 5).
3.5. Metastasis free survival based on Mammoglobin and Mucin-
1 expression and CA 15.3 levels
About 46% of breast cancer patients developed metastasis by
the end of follow up duration. The mean metastasis free sur-
vival time was 32.9 months (95% CI: 27.9, 37.9). Before sur-
gery; the mean metastasis free survival time was 42.6 monthss after surgery and after 6 cycles of chemotherapy with various
Mucin-1 (r,p)*
After surgery After treatment
0.404 0.004 0.288 0.043
0.023 0.325 0.012 0.333 0.018
0.012 0.339 0.016 0.389 0.005
0.023
0.018 0.474 0.001 0.299 0.035
0.000
ce, the correlation is signiﬁcant when p 6 0.05.
the biochemical parameters, 2 weeks after surgery.
Metastasis (22) RR 95% CI
n (%)
6 (33.4)
16 (51.7) 1.4 .85, 2.24
0 (0.0)
22 (52.4) 2.1* 1.53, 2.88
15 (39.5)
7 (58.3) 1.5 .71, 2.98
Table 5 The relative risk for breast cancer metastasis according to the biochemical parameters, after 6 cycles of treatment.
Biochemical parameter No Metastasis (28) Metastasis (22) RR 95% CI
n (%) n (%)
Mammoglobin
ve ** 17 (73.9) 6 (26.1)
+ve 11 (40.7) 16 (59.3) 1.8* 1.10, 3.04
Mucin-1
ve** 17 (73.9) 6 (26.1) 1.8* 1.03, 2.79
+ve 11 (40.7) 16 (59.3)
CA 15.3
ve** 19 (67.9) 9 (32.1) 1.7 .94, 2.91
+ve 9 (40.9) 13 (59.1)
* Signiﬁcant.
** Reference category.
Figure 3 Metastasis free survival in breast cancer females
negative and positive to Mucin-1, 2 weeks after surgery.
Figure 4 Metastasis free survival in breast cancer females
negative and positive to Mammoglobin, after 6 cycles
of treatment.
202 S.A. Ebeed et al.(95% CI: 34.7, 50.5) in Mammoglobin negative compared to
30.4 months (95% CI: 24.7, 36.1) in Mammoglobin positive,
though this apparent difference, the survival distributions were
not statistically signiﬁcantly different (logrank = 2.59,
p= 0.108). For Mucin-1, the mean metastasis free survival
time was 40.3 months (95% CI: 29.5, 51.1) in Mucin-1 negative
compared to 31.7 months (95% CI: 26.2, 37.1) in Mucin-1 po-
sitive, but no signiﬁcant difference was detected between both
survival distributions (logrank = 0.74, p= 0.390). As regards
the CA 15.3, the mean metastasis free survival time was
33.8 months, (95% CI: 28.4, 39.3) in CA 15.3 negative com-
pared to 29 months, (95% CI: 17.2, 40.8) in CA 15.3 positive,
but without statistical signiﬁcant difference in the survival dis-
tributions (logrank = 0.26, p= 0.608).
After surgery; the mean metastasis free survival time was
35.3 months (95% CI: 27.6, 43.1) in Mammoglobin negative
compared to 31.1 months (95% CI: 24.6, 37.6) in Mammoglo-
bin positive, but the difference in survival distributions was not
statistically signiﬁcant (logrank = 1.12, p= 0.291). The
cumulative metastasis free survival distribution was statisti-
cally signiﬁcantly higher in Mucin-1 negative relative to those
that were Mucin-1 positive. (logrank = 5.90, p= 0.015) (The
mean survival times were not computed as all Mucin-1 nega-
tive were censored) (Fig. 3). As regards, CA 15.3 the mean
metastasis free survival time was 34.4 months (95% CI: 28.7,
40.1) in CA 15.3 negative compared to 28.1 months (95%
CI: 18.0, 38.2) in CA 15.3 positive, however the difference in
survival distributions was not statistically signiﬁcant (log-
rank = 1.11, p= 0.292).
After 6 cycles of treatment; a statistically signiﬁcant differ-
ence in the survival distributions was observed between Mam-
moglobin negative and Mammoglobin positive (logrank =
5.15, p= 0.023), with a mean survival time (38.9 months,
95% CI: 32.4, 45.3 vs 27.7 months, 95% CI: 20.8, 34.7 respec-
tively) (Fig. 4). Likewise, a statistically signiﬁcant difference in
the survival distributions was detected between Mucin-1 nega-
tive and Mucin-1 positive (logrank = 4.17, p= 0.041), with a
mean survival time (38.6 months, 95% CI: 32.0, 45.3 in Mucin-
1 negative vs 28.3 months, 95% CI: 21.5, 35.1 in Mucin-1 po-
sitive) (Fig. 5). Meanwhile, the CA 15.3 did not prove a statis-
tically signiﬁcant difference in the survival distributions
between those CA 15.3 negative and those positive (log-
rank = 2.95, p= 0.086), though the mean metastasis free sur-
Figure 5 Metastasis free survival in breast cancer females
negative and positive to Mucin-1, after 6 cycles of treatment.
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ative compared to 27.8 months, 95% CI: 20.3, 35.2 in CA 15.3
positive.
3.6. Evaluation of the accuracy of Mammoglobin and Mucin-1
expression and CA 15.3 levels
The prognostic accuracy for anticipating metastasis of none of
the biochemical parameters was statistically signiﬁcant either
before or after 2 weeks of surgery. On the other hand, after
6 cycles of treatment, Mammoglobin and Mucin-1 proved a
signiﬁcant prognostic accuracy with an AUCs = 0.667, 95%
at CI: 0.515, 0.820 and 0.649, 95% CI: 0.495, 0.804; respec-
tively. While CA 15.3 was not of any prognostic signiﬁcance
with AUC= 0.635, 95% CI: 0.477, 0.792 (Fig. 6).Figure 6 ROC curve for Mammoglobin, Mucin-1 and CA 15.3
as prognostic markers for metastasis in females with breast cancer
after 6 cycles of chemotherapy.When constructing the ROC curve combining both Mam-
moglobin and Mucin-1, considering cases that are Mammoglo-
bin positive and/or Mucin-1 positive as positive, the ROC
curve demonstrated a statistically signiﬁcant diagnostic accu-
racy (p= 0.01) with an AUC= 0.710; 95% CI: 0.566, 0.853;
that was slightly higher than either Mammoglobin alone or
Mucin-1 alone (Fig. 6).
4. Discussion
Breast cancer is the most frequently diagnosed cancer and the
leading cause of cancer death in females worldwide, account-
ing for 23% (1.38 million) of the total new cancer cases and
14% (458,400) of the total cancer deaths in 2008. About half
the breast cancer cases and 60% of the deaths are estimated
to occur in economically developing countries.4 However, de-
spite optimal local and systemic adjuvant treatment, 30–40%
of patients diagnosed with curable breast cancer eventually
die of recurrent disease.13 Therefore, improved techniques to
both detect and treat metastatic breast cancer are needed.
It was previously thought that metastasis occurred late in
disease progression; however, evidence has shown that metas-
tasis may be an early event. This is supported by the fact that
CTCs are found in patients with early breast cancer. A recent
study showed that dissemination of tumor cells can occur at a
pre-invasive stage of the primary tumor and that the presence
of CTCs was independent of tumor size in early human breast
cancer.11 However, even though occult tumor dissemination
may occur early, not all patients with detectable CTCs will de-
velop overt metastases. These CTCs may be in a state of dor-
mancy and the exact mechanism of transition to overt
metastases is unclear.14
For CTCs to be used as surrogates for metastasis, then
accurate and reproducible techniques are needed for CTCs
quantiﬁcation. This is especially important when considering
that CTCs concentration in peripheral blood can be as low
as one per 105–107 cells.15 It is generally thought that molecu-
lar techniques are more sensitive than the immunohistochemi-
cal techniques (IHC), and that the implementation of such
techniques has greatly improved the ability to detect low num-
bers of breast cancer cells. The detection rate of RT-PCR was
greater than that of IHC and the test detected CTCs in samples
that were shown to be negative by IHC. However, studies
showed that the detection of tumor cells in both bone marrow
and blood varied from equal sensitivities for IHC and RT-
PCR to 10 times more sensitivity using RT-PCR rather than
IHC. The difference in the sensitivity depended upon the par-
ticular tumor marker being assayed.16,17
Our study aimed to evaluate using the expression of Mam-
moglobin, a tumor-derived antigen and Mucin 1, a tumor-
associated antigen, to detect CTCs in blood of breast cancer
females as diagnostic and prognostic markers and predictors
of metastasis. Mammoglobin is a 93-amino acid protein
belonging to the uteroglobin/Clara cell protein family of small
epithelial secretory proteins, the secretoglobins.18 It is ex-
pressed in normal breast epithelial cells and is speciﬁcally over-
expressed in breast cancer. Mammoglobin was reported to be
present in more than 80% of breast cancer cases. Thus, hMAG
is promising for its potential diagnostic value as well as its
prognostic indications in breast cancer, especially as it can be
detected almost exclusively in breast cancer.19,20 The other
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membrane bound, glycosylated phosphoprotein. It has a core
protein mass of 120–225 kDa which increases to 250–
500 kDa with glycosylation.21 Mucin-1 was found to be over-
expressed in more than 90% of breast cancers in an undergly-
cosylated form, which makes it not only a candidate for being
a diagnostic and prognostic marker of breast cancer cells, but
also a target for immunotherapy.22
The study included a cohort of 50 females recently diag-
nosed with breast cancer; most of them were of high stage
and high grade. CA 15.3 was elevated in a small proportion
of cases (20%), while Mammoglobin and Mucin expression
was observed in the majority of cases (80% and 86%; respec-
tively). That reﬂects that CTCs detection in blood could be a
much better diagnostic tool than the conventional tumor
markers that are currently in use. In another study that was
conducted to detect CTCs in patients of relatively higher stage
breast cancer, their results were comparable to ours where they
found that expression of CTC genes correctly identiﬁed 71%
of the patients with invasive breast cancer, and 86% of the
node-positive patients at presentation.23 Furthermore, expres-
sion of CTC genes reﬂected the impact of surgery and of che-
motherapy by the signiﬁcant decrease in the percent of patients
that are still positive, especially Mammoglobin expression.
There have been few studies regarding CTCs in early breast
cancer. The reported CTC positivity rate has ranged from
9.4% to 48.6% depending on the method used and the patient
group.24–29 The positivity rates were so much lower than our
study, most probably because they studied low-grade breast
cancer patients, while the majority of patients in the current
study were of high stage. Although CTDs dissemination in
blood is supposed to be an early event in metastasis, its dissem-
ination in primary breast cancer is not well studied. However,
it might not be an early event, and is most probably correlated
with tumor invasiveness or early metastasis. Also the method
used for the detection and the gene whose expression is mea-
sured is another important factor.
Studies have tried to identify primary tumor characteristics
that would predict the presence of CTCs. A recent study by
Krishnamurthy et al. looked at CTCs in stage 1 and 2 breast
cancer patients and found that the presence of CTCs was inde-
pendent of lymph node status, tumor grade, tumor size, and
receptor status.28 This is in contrast with early ﬁndings of
the SUCCESS trial, that reported a positive correlation be-
tween lymph nodes status and CTCs.29 Our results were in
agreement with those of Krishnamurthy et al., where Mammo-
globin and Mucin-1 expressions before surgery were present in
the majority of patients and did not correlate with any of the
clinical parameters. That is probably because the tumor mass
was still present and was seeding more tumor cells into the cir-
culation. From model systems, it was estimated that about 106
tumor cells/g tumor tissues are shed daily into the blood,
although such model calculations might overestimate the num-
ber actually shed in vivo.30,31 Recent studies also showed that
intraoperative shedding of tumor cells into the circulation may
take place.32,33 However, blood is only a temporary compart-
ment for tumor cells, and a signiﬁcant part of circulating tu-
mor cells do not survive. It was reported that a large number
of circulating tumor cells in patients with breast cancer are
apoptotic and therefore might be unable to settle in secondary
organs.34 After surgery, when the tumor mass was removed,
the presence of living tumor cells in the circulation was signif-icantly correlated with tumor size, vascular invasion, stage and
subsequent metastasis, but not with receptor status, grade and
lymph node metastasis.
One goal of CTC detection is to correlate it to disease
progression and response to treatment as a prognostic mar-
ker. Regarding CTCs prognostic role in breast cancer, the
presence of Mucin-1 expression after surgery posed a doubled
risk of metastasis in Mucin-1 positive than in negative pa-
tients, while after chemotherapy, the expression of either
Mammoglobin or Mucin-1 posed a 1.8 relative risk of metas-
tasis than in negative patients. This demonstrates that the
presence of CTCs after surgery of after treatment with adju-
vant chemotherapy could be associated with worse prognosis.
This was further conﬁrmed when considering DFS, where the
same proﬁle was noticed. Patients that were Mucin-1 positive
after surgery had a signiﬁcantly shorter disease free survival
time compared to Mucin-1 negative patients, while after che-
motherapy, patients who showed the expression of Mammo-
globin or Mucin-1 had signiﬁcantly shorter disease free
survival time compared to negative patients (27.7 vs
38.9 months for Mammoglobin and 28.3 vs 38.6 months for
Mucin-1).
Our results were consistent with most of the published data,
though there is a great inconsistency regarding tumor re-
sponse. Several studies involving early breast cancer patients
have shown that the presence of CTCs is associated with a
worse prognosis, early clinical relapse and disease-related
death.27,35–38 In other studies no signiﬁcant correlation was
found between CTC detection and the primary tumors re-
sponse to neoadjuvant therapy and no correlation was found
between CTC response and tumor response.24,39,40 Though
data is inconsistent regarding tumor response, most studies
have found that the presence of CTCs does predict early re-
lapse. The SUCCESS trial found that pretreatment CTC
detection was associated with reduced disease-free survival as
well as overall survival, while post treatment CTC detection
was only associated with reduced disease-free survival.29
The prognostic accuracy for anticipating metastasis of
CTCs detected in peripheral blood by the expression of Mam-
moglobin or Mucin-1 after 6 cycles of chemotherapy proved to
be signiﬁcant with AUCs = 0.667 and 0.649; respectively.
However, due to the heterogenous nature of breast cancer,
many reported that the simultaneous measurement of multiple
markers signiﬁcantly improved the prognostic accuracy of
CTCs. Combining Mammoglobin and Mucin-1 expressions
for CTC detection resulted in improved AUC becoming
0.71, however, the increase was not huge, it was signiﬁcant.
It was not surprising that in the current study, CA 15.3 was
not of any diagnostic or prognostic signiﬁcance and did not
correlate with any of the clinical parameters of the disease
and could not predict metastasis. Currently, CA 15.3, which
detects a soluble form of Mucin-1 protein, is the most widely
used serum marker in patients with breast cancer. Its main
use is for monitoring therapy in patients with metastatic dis-
ease. In this setting, CA 15.3 should not be used alone but in
conjunction with diagnostic imaging, clinical history and phys-
ical examination.41 It may also be used in the postoperative
surveillance of asymptomatic women who have undergone sur-
gery for invasive breast cancer. In this setting, serial determina-
tion can provide median lead-times of 5–6 months in the early
detection of recurrent/metastatic breast cancer. It is unclear
however, whether administering systemic therapy based on this
Diagnostic and prognostic value of circulating tumor cells in female breast cancer patients 205lead-time improves patient outcome. The main limitation of
CA 15.3 as a marker for breast cancer is that serum levels
are rarely increased in patients with early or localized disease.
CA 15.3 increases in some cases only when metastasis has al-
ready happened, probably before clinical symptoms become
visible, but as such it is not of any prognostic value in primary
breast cancer.42,43
In conclusion, the data reported in the present study indi-
cate that the hematogenous spread of tumor cells in patients
with breast cancer may be an early phenomenon occurring be-
fore/apart from regional lymph nodes involvement. CTCs
detection by RT-PCR could add to the initial evaluation of
primary breast cancer patients. Also, adjuvant chemotherapy
might eliminate or decrease occult tumor cells. But CTCs eval-
uation after adjuvant chemotherapy could predict metastasis
and the presence of CTCs after chemotherapy reﬂect a higher
potential for subsequent metastasis. As understanding of the
biology of the breast cancer continues to improve, treatment
of the disease continues to change, although the ultimate goal
of the treatment remains improved survival, increasing empha-
sis is now put on less morbid treatments, and improves quality
of life. Detection of the disease or metastasis remains our goal
for achieving good control of the disease.References
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